文献速递浆细胞疾病

新一代流式细胞术检测多发性骨髓瘤可测量残留病

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.
PubMed 文献 · J Clin Oncol · 2019-11-26

在PETHEMA/GEM2012MENOS65试验中,458例新诊断多发性骨髓瘤患者接受VRD诱导、自体移植和VRD巩固后,采用新一代流式细胞术评估可测量残留病(MRD)。205例(45%)患者巩固后MRD不可测,其进展或死亡风险降低82%(HR 0.18;95%CI 0.11-0.30;95%CI 0.05-0.29;

要点

  • 巩固后MRD不可测者进展或死亡风险显著降低(HR 0.18)。
  • MRD不可测可克服高危细胞遗传学等不良预后因素。
  • R-ISS III期且MRD阳性者预后极差,中位PFS 14个月、OS 17个月。

核心结论

  • IMWG流式MRD阴性标准在MM中适用性高且敏感,可评估治疗疗效。

研究设计与样本

  • PETHEMA/GEM2012MENOS65试验中458例新诊断MM患者纵向评估MRD,397例的1100份骨髓样本用NGF检测,中位检测限2.9×10^-6。

主要发现

  • 205例(45%)患者巩固后MRD不可测,其中仅14例(7%)至今出现进展。
  • MRD不可测的时机(诱导后 vs 强化后)对生存无影响。
  • R-ISS III期且MRD阳性者中位PFS 14个月、中位OS 17个月。
  • 维持治疗使MRD不可测率提高17%。

关键数值与推荐

  • IMWG流式MRD阴性标准:NGF检测骨髓MRD不可测,中位检测限2.9×10^-6。

临床怎么用

  • 可采用NGF流式检测MRD评估MM治疗疗效,MRD不可测提示预后良好。
  • 对R-ISS III期且MRD阳性者应警惕不良预后。

局限性

  • 61例无MRD数据者按意向治疗分析视为MRD阳性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Assessing measurable residual disease (MRD) has become standard with many tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain, particularly when assessed by next-generation flow (NGF) cytometry. Thus, we aimed to determine the applicability and sensitivity of the flow MRD-negative criterion defined by the International Myeloma Working Group (IMWG). PATIENTS AND METHODS: In the PETHEMA/GEM2012MENOS65 trial, 458 patients with newly diagnosed MM had longitudinal assessment of MRD after six induction cycles with bortezomib, lenalidomide, and dexamethasone (VRD), autologous transplantation, and two consolidation courses with VRD. MRD was assessed in 1,100 bone marrow samples from 397 patients; the 61 patients without MRD data discontinued treatment during induction and were considered MRD positive for intent-to-treat analysis. The median limit of detection achieved by NGF was 2.9 × 10-6. Patients received maintenance (lenalidomide ± ixazomib) according to the companion PETHEMA/GEM2014MAIN trial. RESULTS: Overall, 205 (45%) of 458 patients had undetectable MRD after consolidation, and only 14 of them (7%) have experienced progression thus far; seven of these 14 displayed extraosseous plasmacytomas at diagnosis and/or relapse. Using time-dependent analysis, patients with undetectable MRD had an 82% reduction in the risk of progression or death (hazard ratio, 0.18; 95% CI, 0.11 to 0.30; P < .001) and an 88% reduction in the risk of death (hazard ratio, 0.12; 95% CI, 0.05 to 0.29; P < .001). Timing of undetectable MRD (after induction v intensification) had no impact on patient survival. Attaining undetectable MRD overcame poor prognostic features at diagnosis, including high-risk cytogenetics. By contrast, patients with Revised International Staging System III status and positive MRD had dismal progression-free and overall survivals (median, 14 and 17 months, respectively). Maintenance increased the rate of undetectable MRD by 17%. CONCLUSION: The IMWG flow MRD-negative response criterion is highly applicable and sensitive to evaluate treatment efficacy in MM.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Paiva B, Puig N, Cedena MT, et al. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma. J Clin Oncol. 2019. PMID: 31770060. doi:10.1200/JCO.19.01231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。